Which patients with lung cancer are mainly suitable for capmatinib?

Capmatinib is a targeted therapy drug specifically used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. Although the proportion of this type of patients in the lung cancer population is not high (about 3–4%), they have clear pathogenic molecular driving mechanisms. The launch of capmatinib brings new treatment hope to these patients.

The MET gene encodes a tyrosine kinase receptor that plays a key role in cell growth, migration, and survival. MET exon 14 skipping mutations can block MET protein degradation and continuously activate downstream pathways, thereby driving tumor growth. Capmatinib prevents the abnormal proliferation and metastasis of tumor cells by inhibiting this abnormal signaling pathway, and is suitable for patients with such gene mutations.

The target population for capmatinib usually includes the following categories:

1. NSCLC patients with MET exon 14 skipping mutations confirmed by genetic testing regardless of whether they have received systemic treatment in the past;

2. Patients with advanced lung cancer who are resistant or ineffective to traditional chemotherapy or immunotherapy;

3. For older patients with multiple comorbidities and intolerance to traditional chemotherapy regimens, capmatinib provides a relatively mild and targeted treatment path;

It needs to be emphasized that the use of capmatinib needs to be confirmed based on molecular targeted testing, which is also the basic prerequisite for precision medicine treatment. Currently, most authoritative guidelines recommend comprehensive NGS (high-throughput gene sequencing) when lung cancer is diagnosed to identify targetable mutations as early as possible, including EGFR, ALK, ROS1, RET, and MET.

In short, capmatinib is a precise targeted drug clearly targeted at patients with MET mutation-driven NSCLC. Its use marks an important step in the development of a more personalized treatment of lung cancer. Identifying patient groups through genetic testing and standardizing the use of capmatinib under the guidance of doctors can greatly improve the efficacy, prolong survival and improve quality of life.

Reference materials:https://www.drugs.com/mtm/capmatinib.html